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Summary
Background Uncertainties persist about the magnitude of associations of diabetes mellitus and fasting glucose 
concentration with risk of coronary heart disease and major stroke subtypes. We aimed to quantify these associations 
for a wide range of circumstances.
Methods We undertook a meta-analysis of individual records of diabetes, fasting blood glucose concentration, and 
other risk factors in people without initial vascular disease from studies in the Emerging Risk Factors Collaboration. 
We combined within-study regressions that were adjusted for age, sex, smoking, systolic blood pressure, and body-
mass index to calculate hazard ratios (HRs) for vascular disease.
Findings Analyses included data for 698 782 people (52 765 non-fatal or fatal vascular outcomes; 8·49 million person-
years at risk) from 102 prospective studies. Adjusted HRs with diabetes were: 2·00 (95% CI 1·83–2·19) for coronary 
heart disease; 2·27 (1·95–2·65) for ischaemic stroke; 1·56 (1·19–2·05) for haemorrhagic stroke; 1·84 (1·59–2·13) for 
unclassiﬁ ed stroke; and 1·73 (1·51–1·98) for the aggregate of other vascular deaths. HRs did not change appreciably 
after further adjustment for lipid, inﬂ ammatory, or renal markers. HRs for coronary heart disease were higher in 
women than in men, at 40–59 years than at 70 years and older, and with fatal than with non-fatal disease. At an adult 
population-wide prevalence of 10%, diabetes was estimated to account for 11% (10–12%) of vascular deaths. Fasting 
blood glucose concentration was non-linearly related to vascular risk, with no signiﬁ cant associations between 
3·90 mmol/L and 5·59 mmol/L. Compared with fasting blood glucose concentrations of 3·90–5·59 mmol/L, HRs 
for coronary heart disease were: 1·07 (0·97–1·18) for lower than 3·90 mmol/L; 1·11 (1·04–1·18) for 5·60–6·09 mmol/L; 
and 1·17 (1·08–1·26) for 6·10–6·99 mmol/L. In people without a history of diabetes, information about fasting blood 
glucose concentration or impaired fasting glucose status did not signiﬁ cantly improve metrics of vascular disease 
prediction when added to information about several conventional risk factors.
Interpretation Diabetes confers about a two-fold excess risk for a wide range of vascular diseases, independently from 
other conventional risk factors. In people without diabetes, fasting blood glucose concentration is modestly and non-
linearly associated with risk of vascular disease.
Funding British Heart Foundation, UK Medical Research Council, and Pﬁ zer.
Introduction
Diabetes mellitus is an established risk factor for coronary 
heart disease and ischaemic stroke,1,2 but how much its 
eﬀ ect varies by age, sex, or levels of conventional risk 
factors is uncertain.3,4 The extent to which diabetes is 
associated with fatal versus non-fatal myocardial infarction 
or ischaemic versus haemorrhagic stroke is also 
unknown.5,6 Furthermore, how much of the eﬀ ect of 
diabetes on vascular risk can be accounted for by 
conventional vascular risk factors (eg, obesity, lipids, or 
blood pressure) is unresolved.7 Diﬀ erent uncertainties 
apply to measures of dysglycaemia in people without 
diabetes. Fasting blood glucose has been reported to be 
log-linearly and importantly associated with risk of 
vascular disease at all concentrations, including below the 
threshold for diabetes of 7 mmol/L. Available data on this 
topic are, however, inconclusive.8,9 In 2009, the US 
Preventive Services Task Force stated that prospective data 
for fasting blood glucose concentration and coronary heart 
disease were inconsistent and had serious limitations.10 
Furthermore, the value of assessment of fasting blood 
glucose concentration in vascular risk prediction—beyond 
measurement of conventional risk factors—is not 
established.10 We report analyses of individual records of 
people without initial vascular disease in prospective 
studies. We aimed to produce reliable estimates of 
associations of diabetes and fasting blood glucose 
concentration with fatal or ﬁ rst-ever non-fatal incident 
ischaemic vascular disease (and deaths from other vascular 
disorders) for a wide range of circumstances.
Methods
Study design
Details of the Emerging Risk Factors Collaboration have 
been described previously.11 By May, 2010, 121 prospective 
studies of vascular risk factors, involving a total of 
1·27 million adults, had shared individual records 
(webappendix p 2). These studies: (1) did not select See Online for webappendix
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participants on the basis of previous vascular disease; 
(2) recorded cause-speciﬁ c mortality or vascular morbidity, 
or both, using well deﬁ ned criteria; and (3) accrued more 
than 1 year of follow-up. For registration of fatal outcomes, 
all contributing studies used coding from the International 
Classiﬁ cation of Diseases (ICD) to at least three digits (or 
using study-speciﬁ c classiﬁ cation systems), and ascer-
tainment was based on death certiﬁ cates. The webappendix 
(pp 17–20) provides details of the 102 contributing studies 
that had information at baseline on history of diabetes and/
or fasting blood glucose concentration (measured ≥8 h or 
overnight fasting). Acronyms and references for 
contributing studies are shown in the webappendix 
(pp 32–38). 
Statistical analyses
We assessed baseline diabetes status (deﬁ ned by self-
report, medication usage, and/or baseline fasting blood 
glucose concentration ≥7 mmol/L) in relation to coronary 
heart disease (ﬁ rst-ever myocardial infarction or fatal 
coronary heart disease); stroke subtypes (fatal or non-fatal 
ischaemic, haemorrhagic, or unclassiﬁ ed stroke); and 
deaths attributed to the aggregate of other vascular 
disorders (consisting of heart failure, cardiac dysrrhythmia, 
sudden death, hypertensive disease, pulmonary embolism, 
and aortic aneurysm; webappendix p 21). We used a two-
stage approach for analysis, with estimates of association 
calculated separately within each study, then pooled across 
studies by random-eﬀ ects meta-analysis.12,13 Hazard ratios 
(HRs) were calculated with Cox proportional hazards 
regression models that were stratiﬁ ed by sex (and, in the 
few contributing trials, stratiﬁ ed by allocated treatment 
group). We excluded studies with fewer than 11 cases of an 
outcome from the analysis of that outcome. In the ﬁ gures 
presented, sizes of data markers are proportional to the 
inverse of the variance of the HRs. Participants contributed 
only their ﬁ rst non-fatal vascular outcome or death 
recorded at age 40 years or older (ie, deaths preceded by 
non-fatal vascular events were not included in the analyses). 
For the three individually matched nested case-control 
studies within prospective cohorts, we calculated odds 
ratios with conditional logistic regression. Since only 
60 760 participants had LDL cholesterol concentrations 
that had been directly measured, we used non-HDL 
cholesterol as the principal marker of cholesterol content 
in proatherogenic lipoproteins. 
To characterise shapes of associations, study-speciﬁ c 
HRs calculated within overall categories of baseline blood 
glucose concentration were pooled on the log scale, by 
multivariate random-eﬀ ects meta-analysis, and plotted 
against pooled mean concentrations within each category. 
To restrict potential bias related to having a diagnosis of 
diabetes (eg, medication use, changes in lifestyle), we 
assessed separately individuals with and without a history 
of diabetes at baseline. 95% CIs were estimated from the 
variances that show the amount of information underlying 
each group (including the reference group).14 We 
investigated eﬀ ect-modiﬁ cation with formal tests of 
interaction, and calculated p values for interaction using 
continuous variables, when appropriate. Diversity between 
studies was investigated by grouping studies with recorded 
characteristics and meta-regression. We adjusted HRs for 
baseline age, sex, smoking status, BMI, systolic blood 
pressure, and lipids (and, in supplementary analyses, for 
additional factors). Evidence of association was shown by 
the Wald χ² statistic and of heterogeneity by the I² 
statistic.15 We calculated measures of discrimination for 
censored time-to-event data (Harrell’s C index) and 
reclassiﬁ cation, with methods described previously.16 We 
estimated population-attributable fractions with HRs for 
vascular death,17 and undertook sensitivity analyses 
allowing for potential misclassiﬁ cation of diabetes. 
Regression dilution ratios were obtained by regressing 
serial measurements taken from 307 517 participants 
(mean interval 2·6 years) on baseline levels of the relevant 
characteristic and duration of follow-up. In further 
analyses, we corrected for regression dilution in fasting 
blood glucose concentration and covariates, with methods 
described previously.12 We did all analyses using Stata 
(version 11). This study was approved by the 
Cambridgeshire ethics review committee.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. NS and JD had full access to all 
data in the study and had ﬁ nal responsibility to submit 
for publication.
Results
102 studies had relevant information for this analysis. 
From these studies, 698 782 participants had no history 
of myocardial infarction, angina, or stroke at initial 
examination. 410 299 of these had information recorded 
Figure 1: Hazard ratios (HRs) for vascular outcomes in people with versus those without diabetes at baseline
Analyses were based on 530 083 participants. HRs were adjusted for age, smoking status, body-mass index, and 
systolic blood pressure, and, where appropriate, stratiﬁ ed by sex and trial arm. 208 coronary heart disease outcomes 
that contributed to the grand total could not contribute to the subtotals of coronary death or non-fatal myocardial 
infarction because there were fewer than 11 cases of these coronary disease subtypes in some studies. *Includes 
both fatal and non-fatal events.
Number
of cases
HR (95% CI) I² (95% CI)
Coronary heart disease* 26 505 2·00 (1·83–2·19) 64 (54–71)
Coronary death 11 556 2·31 (2·05–2·60) 41 (24–54)
Non-fatal myocardial infarction 14 741 1·82 (1·64–2·03) 37 (19–51)
Stroke subtypes*   
Ischaemic stroke 3799 2·27 (1·95–2·65) 1 (0–20)
Haemorrhagic stroke 1183 1·56 (1·19–2·05) 0 (0–26)
Unclassiﬁed stroke 4973 1·84 (1·59–2·13) 33 (12–48)
Other vascular deaths 3826 1·73 (1·51–1·98) 0 (0–26)
1 2 4
Articles
www.thelancet.com   Vol 375   June 26, 2010 2217
about self-reported history of diabetes, but not fasting 
blood glucose concentration; 195 390 had information on 
both self-reported diabetes and fasting blood glucose; 
and 93 093 had information for fasting blood glucose, but 
not self-reported diabetes (data for participants with 
information about fasting glucose but not self-reported 
diabetes contributed to analyses of fasting blood glucose 
concentration, but did not contribute to analyses of 
diabetes). 264 353 participants had complete information 
at baseline for self-reported history of diabetes, age, sex, 
smoking habits, systolic blood pressure, BMI, high-
density lipoprotein (HDL) cholesterol, total cholesterol 
concentrations, and triglyceride concentration. Deaths 
were classiﬁ ed by ICD coding, and 70 of 102 contributing 
studies also used medical records, autopsy ﬁ ndings, and 
other supple mentary sources. 73 studies used standard 
deﬁ nitions of myocardial infarction that were based on 
WHO criteria. For 75 studies, investigators provided 
information about stroke subtype. For 59 studies, 
investigators reported diagnosis of strokes on the basis of 
typical clinical features and brain imaging. Information 
was generally not available for diabetes type (ie, whether 
type 1 or 2 diabetes) or diagnosis of diabetes and 
microvascular disease after baseline.
Overall, the mean age of participants at entry was 
52 (SD 13) years, and 300 051 (43%) were women. 
669 506 (96%) were in Europe, North America, and 
Australasia, with the remainder in Japan or the 
Caribbean. Of the participants with information on self-
reported history of diabetes, 38 851 (7%) reported a 
history of diabetes at baseline. Diabetes prevalence 
varied across studies, partly aﬀ ected by diﬀ erences in 
sex distribution (webappendix p 3, 22). Baseline mean 
glucose concentrations were similar across studies 
(webappendix p 4). In people without known diabetes, 
glucose concentration was associated with obesity, 
blood pressure, lipid concentration, and inﬂ ammatory 
markers (webappendix p 5). In this group, serial 
measurements yielded an age-adjusted and sex-adjusted 
regression dilution ratio of 0·69 (95% CI 0·66–0·72; 
webappendix p 6) for fasting blood glucose 
concentration, 0·64 (0·62–0·65) for non-HDL 
cholesterol, and 0·51 (0·49–0·53) for systolic blood 
pressure. During 8·49 million person-years at risk 
(median 10·8 years to ﬁ rst outcome), 52 765 incident 
fatal or ﬁ rst-ever non-fatal vascular disease outcomes 
were recorded (webappendix pp 23–26).
In comparison of people with diabetes versus those 
without, HRs adjusted for age, sex, smoking status, 
BMI, and systolic blood pressure (basic covariates) were 
about two for coronary heart disease, ischaemic stroke, 
unclassiﬁ ed stroke, and deaths attributed to other 
vascular diseases (HR for haemorrhagic stroke was 
somewhat lower). HRs were about a third higher for 
coronary death than for non-fatal myocardial infarction 
(ﬁ gure 1). 
HRs for coronary heart disease with diabetes were 
signiﬁ cantly higher in women than in men, at 40–59 years 
than at 70 years or older, in non-smokers than in smokers, 
and at below average BMI or below average systolic blood 
pressure (ﬁ gure 2). HRs for coronary heart disease did not 
vary much by other characteristics (including by 
geographical location or in people who are of white 
European ancestry versus those who are not; webappendix 
p 7). HRs for coronary heart disease did not change 
substantially after additional adjustment for non-HDL 
Figure 2: Hazard ratios (HRs) for coronary heart disease and ischaemic stroke in people with versus those without diabetes at baseline, by individual characteristics
HRs were adjusted as described in ﬁ gure 1. BMI=body-mass index. *Bottom third=<23·8 kg/m² (mean 21·7 kg/m²); middle third=23·8–<27 kg/m² (mean 25·3 kg/m²); and top third=≥27 kg/m² (mean 
30·7 kg/m²). †Bottom third=<123 mm Hg (mean 113 mm Hg); middle third=123–<141 mm Hg (mean 132 mm Hg); and top third=≥141 mm Hg (mean 157 mm Hg).
Sex
Male 306 533 20 218 1·89 (1·73–2·06) <0·0001
Female 223 550 6287 2·59 (2·29–2·93) 
Age at survey
40–59 years 410 833 17 686 2·51 (2·25–2·80) <0·0001
60–69 years 75 785 5045 2·01 (1·80–2·26) 
≥70 years 43 465 3774 1·78 (1·54–2·05) 
Smoking status
Other 343 864 13 702 2·35 (2·11–2·61) <0·0001
Current 186 219 12 803 1·82 (1·65–2·00) 
BMI*
Bottom third 176 274 6701 2·30 (2·00–2·64) 0·0143
Middle third 176 332 9103 2·45 (2·15–2·79) 
Top third 177 477 10 701 1·98 (1·76–2·21) 
Systolic blood pressure†
Bottom third 183 314 4915 2·85 (2·48–3·27) <0·0001
Middle third 192 622 9079 2·31 (2·05–2·60) 
Top third 154 147 12 511 1·97 (1·78–2·18) 
  168 191 2193 2·16 (1·84–2·52) 0·0089
  125 571 1606 2·83 (2·35–3·40) 
  234 263 1729 3·74 (3·06–4·58) 0·0001
  38 140 1134 2·06 (1·64–2·58) 
  21 359 936 1·80 (1·42–2·27) 
  191 125 2471 2·58 (2·19–3·05) 0·1355
  102 637 1328 2·18 (1·76–2·69) 
  110 044 1149 1·90 (1·50–2·40) 0·0001
  97 478 1163 2·28 (1·85–2·80) 
  86 240 1487 2·90 (2·49–3·37) 
  113 199 711 3·06 (2·33–4·01) 0·7275
  106 966 1217 2·79 (2·23–3·49) 
  73 597 1871 2·49 (2·02–3·07) 
Number
of cases
Number 
of partici-
pants
Coronary heart diseaseA
HR (95% CI) Interaction
p value
Number
of cases
Number 
of partici-
pants
HR (95% CI) Interaction
p value
Ischaemic strokeB
1 2 4 1 2 4 6
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cholesterol, HDL cholesterol, and triglyceride concentration 
(ﬁ gure 3). HRs for coronary heart disease were similar 
when: adjustment was made for apolipoprotein AI and 
apolipoprotein B instead of HDL cholesterol and non-HDL 
cholesterol, respectively; waist-to-hip ratio replaced BMI; 
or additional adjustment was made for ﬁ brinogen, 
C-reactive protein, or estimated glomerular ﬁ ltration rate 
(webappendix p 27). HRs for ischaemic stroke, adjusted for 
basic covariates, were higher in women, in people aged 
between 40 and 59 years, and in people with above average 
BMI (ﬁ gure 2, webappendix p 7). HRs for ischaemic stroke 
did not change greatly after additional adjustment for 
lipids (ﬁ gure 3). 
In analyses adjusted for basic covariates, fasting blood 
glucose concentration was non-linearly related to risk 
of coronary heart disease or ischaemic stroke (ﬁ gure 4), 
and unrelated to vascular risk between 3·90 and 
5·59 mmol/L (webappendix p 8). In people with no 
history of diabetes at baseline, compared with people 
with fasting blood glucose concentrations of 
3·90–5·59 mmol/L, risk of coronary heart disease was 
only modestly higher in those with fasting blood glucose 
concentrations between 5·60 mmol/L and 6·99 mmol/L 
(ie, impaired fasting glucose), but substantially higher 
in those with fasting blood glucose concentrations of 
7 mmol/L or higher (ﬁ gure 5). Compared with the same 
reference group, risk of coronary heart disease was 
substantially higher in people with a history of diabetes. 
HRs were about 50% higher in people with a history of 
diabetes and with fasting blood glucose concentrations 
Figure 3: Hazard ratios (HRs) for coronary heart disease and ischaemic stroke in people with versus those without diabetes, progressively adjusted for 
baseline levels of conventional risk factors
Analyses were based on 264 353 participants (11 848 cases) for coronary heart disease and 157 315 participants (2858 cases) for ischaemic stroke with complete 
information on all covariates listed. BMI=body-mass index.
Adjusted for
Age and sex 2·06 (1·82–2·34)
Plus smoking status 2·10 (1·85–2·39)
Plus BMI 2·00 (1·78–2·25)
Plus systolic blood pressure 1·91 (1·70–2·14)
Plus non-HDL cholesterol 1·93 (1·71–2·16)
Plus HDL cholesterol 1·87 (1·67–2·09)
Plus log-triglyceride 1·87 (1·67–2·09)
Adjusted for
Age and sex 2·56 (2·15–3·05)
Plus smoking status 2·59 (2·16–3·09)
Plus BMI 2·45 (2·08–2·88)
Plus systolic blood pressure 2·27 (1·94–2·65)
Plus non-HDL cholesterol 2·26 (1·94–2·64)
Plus HDL cholesterol 2·24 (1·94–2·60)
Plus log-triglyceride 2·24 (1·94–2·59)
A Coronary heart disease
HR (95% CI)
B Ischaemic stroke
HR (95% CI)
1 2 41 2 4
Figure 4: Hazard ratios (HRs) for coronary heart disease and ischaemic stroke by baseline fasting blood glucose concentration
Analyses were based on 279 290 participants (14 814 cases) for coronary heart disease (CHD) and 175 542 participants (1754 cases) for ischaemic stroke. Participants 
without known diabetes at baseline were classiﬁ ed into groups of fasting glucose (CHD: <4·0, 4·0–4·5, 4·5–5·0, 5·0–5·5, 5·5–6·0, 6·0–6·5, 6·5–7·0, 7·0–7·5, and 
>7·5 mmol/L; ischaemic stroke: <4·5, 4·5–5·0, 5·0–5·5, 5·5–6·0, 6·0–7·0, and >7·0 mmol/L). HRs were adjusted as described in ﬁ gure 1 and are plotted against mean 
fasting blood glucose in each group. Reference group for both outcomes is 5·0–5·5 mmol/L. 
H
R 
(9
5%
 C
I)
Mean fasting blood glucose concentration (mmol/L)
109876543
4·0
3·0
2·0
1·0
0
Coronary heart diseaseA
No known history of diabetes at baseline survey
Known history of diabetes at baseline survey
Mean fasting blood glucose concentration (mmol/L)
0 0 109876543
Ischaemic strokeB
Figure 5: Hazard ratios (HRs) for coronary heart disease by clinically deﬁ ned categories of baseline fasting 
blood glucose concentration
Analyses were based on 279 290 participants (14 814 cases). HRs were adjusted as described in ﬁ gure 1. HR 
(95% CI) in people with fasting glucose 5·60–6·99 mmol/L was 1·12 (1·06–1·18). *Reference group. 
Number of 
participants (%)
HR (95% CI)Number 
of cases
Known diabetes at baseline
≥7 mmol/L 13 122 (4·7%) 1186 2·36 (2·02–2·76)
<7 mmol/L 5807 (2·1%) 380 1·61 (1·42–1·82)
No known diabetes at baseline
≥7 mmol/L 7240 (2·6%) 452 1·78 (1·56–2·03)
6·1 to <7 mmol/L 19 607 (7·0%) 1011 1·17 (1·08–1·26)
5·6 to <6·1 mmol/L 32 008 (11·5%) 1631 1·11 (1·04–1·18)
3·9 to <5·6 mmol/L* 185 590 (66·5%) 9508 1·00 (0·95–1·06)
<3·9 mmol/L 15 916 (5·7%) 646 1·07 (0·97–1·18)
10·8 2 4
Fasting blood glucose
concentration
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of at least 7 mmol/L than in people with a history of 
diabetes but fasting glucose concentrations lower than 
7 mmol/L (ﬁ gure 5). HRs for those with impaired 
fasting blood glucose did not vary materially by age, 
sex, or other recorded characteristics (webappendix p 9). 
At fasting blood glucose concentrations higher than 
5·6 mmol/L, HR per 1 mmol/L higher concentration 
was 1·12 (1·08–1·15) for coronary heart disease, 
assuming existence of log-linear associations above this 
threshold (although data were insuﬃ  cient to conﬁ rm or 
refute this assumption: webappendix p 15). Whereas 
long-term average (usual) concentrations of fasting 
blood glucose were non-linearly and moderately 
associated with risk of coronary heart disease, usual 
levels of total (or non-HDL) cholesterol and systolic 
blood pressure were nearly log-linearly and more 
strongly associated with such risk (ﬁ gure 6). When 
added to a vascular risk-prediction model containing 
age, sex, smoking status, systolic blood pressure, and 
HDL and total cholesterol, information about history of 
diabetes signiﬁ cantly increased the C index (p<0·0001). 
By contrast, in people without diabetes at baseline, such 
addition of information on impaired fasting glucose 
status (p=0·24) or fasting blood glucose concentration 
(p=0·26) did not signiﬁ cantly increase the C index 
(webappendix p 28). Findings based on measures of 
reclassiﬁ cation for 10-year predicted risk yielded 
broadly similar results to those with the C index 
(webappendix p 28).
We noted similar ﬁ ndings in analyses that: used ﬁ xed-
eﬀ ect models, fractional polynomials, or spline terms 
(webappendix pp 10–11); compared larger and smaller 
studies (webappendix pp 12–13); assessed interactions by 
sex and age group; excluded initial follow-up (eg, the ﬁ rst 
5 years); omitted 71 048 (10%) participants known to be 
receiving lipid-lowering, blood pressure-lowering, or 
other cardiovascular drugs at baseline; included fatal 
outcomes without censoring previous non-fatal outcomes; 
stand ardised glucose values in studies that used samples 
other than plasma;18 and assessed associations with 
fasting blood glucose concentration, either ignoring 
history of diabetes at baseline (webappendix p 14) or 
excluding studies that did not record self-reported history 
of diabetes. 
The overall age-adjusted prevalence of diabetes in adults 
was 7·0% (6·1–7·9%)—which is lower than some con-
temporary estimates of about 10% for developed countries.19 
Assuming a population-wide diabetes prevalence of 10% 
(ie, corresponding to a prevalence of 20% in cases of 
vascular death), 11% (10–12%) of vascular deaths are 
estimated to be attributable to diabetes (webappendix p 30), 
or 325 000 vascular deaths per year in the 49 high-income 
H
R 
(9
5%
 C
I)
Mean fasting blood glucose concentration (mmol/L)
4 5 6 7 8 3 4 5 6 7 8
1·0
0
2·0
3·0
4·0
Fasting blood glucose A
Mean cholesterol concentration (mmol/L)
Total and non-HDL cholesterolB
Mean systolic blood pressure (mm Hg)
120 130 140 150 160 170 180
Systolic blood pressureC
Total cholesterol
Non-HDL cholesterol*
Figure 6: Comparison of hazard ratios (HRs) for coronary heart disease by long-term average concentrations of fasting blood glucose concentration, total (and non-HDL) cholesterol, and 
systolic blood pressure, in a common set of participants
Analyses were done in participants with no known history of diabetes at baseline. Analyses of fasting blood glucose concentration, total cholesterol, and systolic blood pressure were based on 
140 624 participants (10 667 cases). For fasting blood glucose, participants were classiﬁ ed into groups of baseline fasting concentrations, as described in ﬁ gure 4. For the other factors presented, 
participants were classiﬁ ed according to baseline values as follows: total cholesterol, <4·5, 4·5–5·1, 5·1–5·7, 5·7–6·3, 6·3–6·9, 6·9–7·5, 7·5–8·1, 8·1–8·7, ≥8·7 mmol/L; non-HDL cholesterol, <3, 
3–3·6, 3·6–4·2, 4·2–4·8, 4·8–5·4, 5·4–6·0, 6·0–6·6, 6·6–7·2, ≥7·2 mmol/L; systolic blood pressure: <110, 110–120, 120–130, 130–140, 140–150, 150–160, 160–170, 170–180, ≥180 mm Hg). These 
categories approximately correspond to those used for fasting blood glucose concentration (ie, increments of half the SD of each factor). HRs were adjusted, where appropriate, for age, smoking 
status, BMI, systolic blood pressure, total cholesterol and fasting blood glucose, and stratiﬁ ed, where appropriate, by sex and trial arm. HRs were plotted against the mean value in each group. 
Long-term average values were calculated with information from serial measurements. The reference group for each factor is the category with the lowest HR. *Analyses of non-HDL cholesterol 
were based on a subset of 71 224 participants (4290 cases).
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countries deﬁ ned by WHO.20 For a hypothetical population-
wide adult prevalence of diabetes of 20%, we estimated 
that 22% (20–23%) of vascular disease would be attributable 
to diabetes. Webappendix p 16 and p 31 provide sensitivity 
analyses, including estimation of the potential eﬀ ect on 
HRs of misclassiﬁ cation of diabetes status.
Discussion
Our analysis has shown that diabetes confers about a two-
fold excess risk for coronary heart disease, major stroke 
subtypes, and deaths attributed to other vascular causes. 
This pattern of strong associations of diabetes with each 
of several diﬀ erent vascular diseases contrasts with that of 
LDL cholesterol (or non-HDL cholesterol), which is 
strongly related to coronary heart disease, but modestly 
related to ischaemic stroke, and unrelated to haemorrhagic 
stroke in prospective observational studies.12 Diabetes is 
about a third more strongly related to fatal than to non-
fatal myocardial infarction, perhaps suggestive of more 
severe forms of coronary lesions in people with diabetes 
than in those without, diﬀ erential response of the 
myocardium to ischaemia, or possibly in part, diﬀ erential 
coding of deaths from coronary heart disease.21–23 Although 
diabetes is a strong risk factor for coronary heart disease 
in all clinically relevant subgroups that we assessed, HRs 
are signiﬁ cantly greater in some groups at lower absolute 
risk of vascular disease—ie, in women, younger ages, 
non-smokers, and at lower-than-average blood pressure. 
Further investigation is needed to establish any 
implications of such eﬀ ect modiﬁ cation. Because only a 
small part of the association between diabetes and 
ischaemic vascular disease is accounted for by several 
conventional and emerging risk factors, other mechanisms 
(including those as yet undiscovered) might be involved.
Our data suggest that in this decade about 10% of 
vascular deaths in populations in developed countries 
have been attributable to diabetes in adults, 
corresponding to an estimated 325 000 deaths per year 
in high-income countries alone (plus several-fold more 
people disabled by vascular disease). This burden will 
increase if the incidence of diabetes continues to rise,19 
even if rates of vascular disease continue to fall because 
of decreases in smoking, improvements in treatment, 
or other reasons. At a diabetes prevalence of 20% in the 
general adult population (ie, more than twice the present 
levels in developed countries), an estimated 20% of 
vascular deaths would be attributable to diabetes. 
Increasing rates of obesity worldwide will probably 
heighten the absolute risk for diabetes and vascular 
disease.27 However, how these trends will modify the 
proportional eﬀ ect of diabetes on risk of vascular disease 
is unclear. For example, HRs for ischaemic stroke seem 
somewhat greater at higher than at lower BMI, whereas 
HRs for coronary heart disease seem greater at lower 
than at higher BMI. 
In contrast with the strong associations observed 
between diabetes and vascular outcomes, our study 
shows much more moderate associations of impaired 
fasting glucose status with coronary heart disease and 
stroke. Furthermore, there were no material associations 
with vascular risk at fasting blood glucose concentrations 
between 3·9 mmol/L and 5·6 mmol/L. By contrast, we 
have shown in a common set of participants that total 
(or non-HDL) cholesterol and systolic blood pressure 
each have much stronger and nearly log-linear 
associations with vascular risk. Additionally, we 
identiﬁ ed that, in people without diabetes, assessment 
of fasting blood glucose concentration or of impaired 
fasting glucose status does not signiﬁ cantly improve 
vascular disease prediction beyond the information 
provided by several conventional risk factors. Fasting 
blood glucose concentration is, of course, measured for 
other purposes, such as identiﬁ cation of diabetes.24 
Scientiﬁ c guideline statements, risk assessment 
strategies, sample sizes for intervention studies, and 
burden of disease calculations have been premised on 
the existence of stronger and log-linear associations 
between fasting blood glucose concentration and 
vascular disease throughout the range of its values.18,25,26 
Review of these eﬀ orts might be useful, therefore, given 
the revised epidemiological estimates provided by our 
ﬁ ndings.
Our study was powered to characterise reliably several 
previously uncertain features, including: HRs for 
ischaemic vascular disease in several clinically relevant 
subgroups; HRs for vascular disease subtypes (eg, major 
stroke subtypes); shapes of relations across the range of 
fasting blood glucose concentrations; and predictive value 
of diabetes, impaired fasting glucose, and fasting blood 
glucose concentration for vascular risk assessment. 
Nevertheless, even more powerful analyses than those 
reported here are needed to characterise reliably shapes 
of associations in speciﬁ c subgroups. For example, the 
present data seem to suggest the existence of some 
continuous association between fasting blood glucose 
concentration and coronary heart disease above an as yet 
imprecisely deﬁ ned threshold.
The generalisability of our ﬁ ndings to populations in 
developed countries is supported by broadly consistent 
results across 102 cohorts in 25 countries. Because our 
data derive mostly from high-income countries, however, 
we could not estimate vascular disease burden attributable 
to diabetes for low-income and middle-income countries. 
Sensitivity analyses suggest that plausible degrees of 
misclassiﬁ cation were unlikely to change reported HRs 
substantially. Conversely, any preferential diagnosis of 
vascular disease in people with diabetes would have 
tended to overestimate HRs. We did not have information 
about duration or age of onset of diabetes or prevalence 
of diabetes type (type 1 or 2), although the age distribution 
suggests that the majority of participants with diabetes 
would have type 2 diabetes. Future prospective studies 
should aim to include additional markers of dysglycaemia 
and insulin resistance.28–30
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